Aktie 603229 ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Zhejiang Ausun Pharmaceutical Co., Ltd.

Aktien

603229

CNE100002XK2

603229

Schlusskurs Shanghai S.E.
Andere Börsenplätze
 00:00:00 17.04.2024 		% 5 Tage % 1. Jan.
9,97 CNY +4,40 % Intraday Chart für Zhejiang Ausun Pharmaceutical Co., Ltd. -5,23 % -24,53 %
2023 Zhejiang Ausun Pharmaceutical Co., Ltd. meldet Ergebnis für die neun Monate bis zum 30. September 2023 CI
2023 Zhejiang Ausun Pharmaceutical Co., Ltd. meldet Ergebnis für das am 30. Juni 2023 endende Halbjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it has received CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd.
Ausun Pharma's Unit Passes Regulatory Inspection
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd.
Zhejiang Ausun Pharma Sees Up to 70% Jump in 2022 Profit; Shares Rose 4%
Zhejiang Ausun Pharma Gets Regulatory Nod to Market Azvudine
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it has received CNY 484.90308 million in funding from Gongqingcheng Shengheng Investment Management Co., Ltd., Shanghai Panjing Investment Management Center (Limited Partnership), Taizhou Financial Holding Asset Management Co., Ltd., and other investors
Marvel Biosciences Completes Manufacturing Milestone Ahead of Phase 1 Trials Targeting Alzheimer's Disease, Depression
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Zhejiang Ausun Pharmaceutical Co., Ltd.(XSSC:603229) added to S&P Global BMI Index
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding from Gongqingcheng Shengheng Investment Management Co., Ltd., Shanghai Panjing Investment Management Center (Limited Partnership), Taizhou Financial Holding Asset Management Co., Ltd.
Algernon Pharmaceuticals Inc. Announces Award Contract to Zhejiang Ausun Pharmaceutical Co, Ltd of China to Begin the Manufacturing of Cgmp Supply of Its Repurposed Drug Candidate Np-251
Chinese Shares End Lower; Pharmaceutical Stlocks Suffer Huge Losses After WuXi Biologics' US Sanction
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 603229 Aktie
  4. Nachrichten Zhejiang Ausun Pharmaceutical Co., Ltd.
  5. Andere Sprachen